Literature DB >> 34186414

The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing.

Carina Eklund1, Laila Sara Arroyo Mühr1, Camilla Lagheden1, Ola Forslund2, Karin Dahlin Robertsson3, Joakim Dillner4.   

Abstract

BACKGROUND: Accurate and internationally comparable human papillomavirus (HPV) testing services are essential for cervical cancer elimination programs. The WHO HPV Laboratory Network started issuing international HPV testing proficiency panels in 2008.
OBJECTIVES: We report the results of the 2019 global proficiency study and evaluate the proficiency over time. STUDY
DESIGN: The proficiency panel contained 40 coded samples containing mixes of purified HPV types (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/68a/68b) and 4 controls. Proficiency required detection of both single and multiple infections of 50 International Units of HPV 16/18, of 500 genome equivalents (10x higher concentration) for other HPV types, and no false positives (stricter requirement compared to previous panels).
RESULTS: Seventy-eight laboratories submitted 110 datasets with 38 different assays. Most samples (38/44) were reported with 100% proficiency in most datasets. Mostly commercial assays were used (88/110 datasets). Overall, 47.3% of the datasets were 100% proficient. False positivity was detected in at least one sample in 30.1% of datasets. When analysing all datasets ever since 2008 using exactly the same proficiency criteria, there was a steady improvement up to 2017 (the proportion of datasets being completely proficient increased from 25% to 73%). However, in the 2019 proficiency testing the proportion of fully proficient datasets dropped to 50%.
CONCLUSIONS: Although we initially documented a worldwide improvement in comparability and reliability of HPV testing services, the trend now appears to be reversed. In response, the International HPV Reference Center will provide support for improved quality of laboratory services, including issuing of global proficiency panels every year.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Cervical cancer; Human papillomavirus; International standards; Quality assurance; cancer eradication

Year:  2021        PMID: 34186414     DOI: 10.1016/j.jcv.2021.104902

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  4 in total

1.  Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples.

Authors:  François Coutlée; Alexandra de Pokomandy; Ann N Burchell; Mariam El-Zein; Marie-Hélène Mayrand; Sophie Rodrigues-Coutlée; Deborah Money; Émilie Comète; Elisabeth McClymont; Danielle Rouleau; Eduardo L Franco
Journal:  J Med Virol       Date:  2022-01-28       Impact factor: 20.693

2.  Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.

Authors:  Rita Mariel Correa; Armando Baena; Joan Valls; María Celeste Colucci; Laura Mendoza; Maryluz Rol; Carolina Wiesner; Annabelle Ferrera; María Dolores Fellner; Joaquín Víctor González; Jorge Alejandro Basiletti; Pamela Mongelos; Mercedes Rodriguez de la Peña; Agustina Saino; Elena Kasamatsu; Carlos Velarde; Ninoska Macavilca; Sandra Martinez; Gino Venegas; Alejandro Calderón; Guillermo Rodriguez; Hernán Barrios; Rolando Herrero; Maribel Almonte; María Alejandra Picconi
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

3.  Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.

Authors:  Laila Sara Arroyo Mühr; Carina Eklund; Camilla Lagheden; Ola Forslund; Karin Dahlin Robertsson; Joakim Dillner
Journal:  J Clin Virol       Date:  2022-07-05       Impact factor: 14.481

4.  HPV screening in the urine of transpeople - A prevalence study.

Authors:  Sophie Pils; Jana Mlakar; Mario Poljak; Grega Gimpelj Domjanič; Ulrike Kaufmann; Stephanie Springer; Andreas Salat; Eva Langthaler; Elmar A Joura
Journal:  EClinicalMedicine       Date:  2022-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.